摘要
目的:探讨窄谱中波紫外线(NB-UVB)局部照射联合退白汤内服治疗白癜风的临床疗效和安全性。方法:将120例白癫风患者随机分为3组,每组40例,治疗组予NB-UVB局部照射,初始剂量为0.5J/cm2,2次/w,每次剂量递增10%~20%,至出现红斑时维持治疗,内服退白汤,2次/d;对照Ⅰ组单纯内服退白汤;对照Ⅱ组单纯使用NB-UVB局部照射,方法均同治疗组,3组均连续治疗12周,分别于治疗第4、8和12周时评价临床疗效。结果:治疗组、对照Ⅰ组、对照Ⅱ组治疗12周时的有效率分别为77.5%、55.0%和47.5%,治疗组与对照Ⅰ组、对照Ⅱ组比较差异均有统计学意义。治疗组皮损开始复色时间明显早于对照Ⅰ组、对照Ⅱ组,P<0.01。治疗组不良反应发生率为12.5%,对照Ⅰ组为7.5%,对照Ⅱ组为12.5%,3组比较,差异均无统计学意义。结论:NB-UVB局部照射联合退白汤内服治疗白癜风疗效确切,安全性好,值得皮肤科临床推广应用。
To investigate the clinical effect and safety of narrow-band ultraviolet B ( NB-UVB ) patial irradiation combined with Tuibai Decoction taken orally in the treatment of vitiligo. Methods :120 cases of vitiligo patients were randomly divided into 3 groups, 40 cases in each group, the treatment group treated with NB-UVB irradiation, the initial dose was 0.5J/cm2,2 times per week, each dose increasing 10%- 20%, and maintain the dose when erythema appeared, taken orally of Tuibai Decoction, 2 times per day. Control group I merely took Tuibai Decoction orally; Control group Ⅱ only use NB-UVB partial irradiation, methods were the same with the treatment group. 3 groups were treated for 12 weeks continuously, and the clinical effect were evaluated respectively in the treatment of 4, 8 and 12 weeks. Results: The effect ratios of treatment group, control group Ⅰ , and control group Ⅱ were 77.5%, 55% and 47.5% respectively after 12 weeks of treat- ment. The differences were statistically significant when treatment group compared with control group I and control group Ⅱ. ( P 〈 0.05or P 〈 0.01 ). Color-recovering starting time of treatment group was significantly earlier than control group I and control group Ⅱ, and the differ- ences were statistically significant ( P 〈 0.01 ). The incidence of adverse reaction of treatment group was 12.5%, 7.5% in control group I and 12.5% in control group Ⅱ , the difference was not statistically significant when the 3 groups compared with each other( P 〉 0.05 ). Conclusion: Clinical effect of NB-UVB partial irradiation combined with Tuibai Decoction taken orally in the treatment of vitiligo is definite , with good safety, worthy of clinical popularization and application in the department of dermatology.
出处
《中药药理与临床》
CAS
CSCD
北大核心
2013年第2期187-189,共3页
Pharmacology and Clinics of Chinese Materia Medica
基金
南通市指令性社会发展科技计划项目(编号:S2009047)